This product is a compounding-pharmacy injection that pairs LIPO-C — itself a fixed-ratio lipotropic cofactor blend — with Vitamin B12 (cobalamin). Each has its own VialTalk monograph: LIPO-C and Vitamin B12. It is marketed for "metabolic support" and "energy," usually in body-composition and wellness-clinic contexts, and is commonly supplied as a weekly injection. The distinctive feature of this entry is that it is effectively a blend of a blend plus a vitamin: LIPO-C is not a single molecule but a compounded mixture of metabolic cofactors (methionine, choline, L-carnitine, and a pantothenic-acid derivative), and several LIPO-C formulas already include B12 — so "LIPO-C + Vitamin B12" often denotes LIPO-C with cobalamin explicitly added or standardised rather than a wholly new pairing. This monograph summarises the components, the limited rationale for combining them, and why the blend is harder to study and to dose than any single compound.
Chemical identity and structure.
There is no single molecular formula; every component keeps its own identity and pharmacokinetics. LIPO-C is a 503A compounding-pharmacy preparation with no standardised formula — the most commonly cited version (the Empower Pharmacy formula) is methionine 15 mg/mL, choline chloride 50 mg/mL, L-carnitine 50 mg/mL, and dexpanthenol (vitamin B5) 5 mg/mL in water for injection, though compositions vary between compounders and some already contain B12. Vitamin B12 here is injectable cobalamin — either cyanocobalamin (C₆₃H₈₈CoN₁₄O₁₄P, MW ≈ 1355 g/mol, the cyanide-bound stable form) or methylcobalamin (C₆₃H₉₁CoN₁₃O₁₄P, MW ≈ 1344 g/mol, the active methyl-bound form); both are cobalt-corrin compounds giving the characteristic deep red-pink solution. Because the contents depend entirely on the compounder, the COA's per-component breakdown — not the "LIPO-C + B12" label — is the controlling identity. See the individual VialTalk monographs for per-component chemistry.
Mechanism of action.
The components are metabolic cofactors and a vitamin rather than receptor-targeted drugs, so the mechanism is the sum of their biochemistry. Within LIPO-C: methionine feeds one-carbon metabolism and methylation, including phosphatidylcholine synthesis; choline is the direct precursor of phosphatidylcholine and is required for hepatic VLDL assembly and lipid export; L-carnitine shuttles long-chain fatty acids into mitochondria for β-oxidation; and dexpanthenol is a precursor of coenzyme A. Vitamin B12 is an essential cofactor for methionine synthase (which remethylates homocysteine to methionine) and methylmalonyl-CoA mutase. There is a genuine point of convergence: methionine synthase requires methylcobalamin to regenerate methionine and, downstream, S-adenosylmethionine — the methyl donor the phosphatidylcholine pathway draws on. So B12 and the LIPO-C methyl-donor cofactors both feed one-carbon/methylation metabolism, which is the coherent rationale for pairing them. That convergence is real biochemistry, but it is a rationale for the combination — not evidence that the combination produces the marketed metabolic or body-composition effect.
Research applications and the evidence base.
The evidence base is per-component, uneven, and — critically — does not line up with how the product is marketed. Vitamin B12 has the strongest base by far: it is FDA-approved with hundreds of controlled trials, but for cobalamin deficiency (including pernicious anaemia) and related neurological and metabolic disorders — not for boosting energy or metabolism in people who are not deficient, where controlled support is lacking. LIPO-C has essentially no controlled Phase III trials of its specific composition for the marketed body-composition indication; its component ingredients have stronger single-agent evidence (for example L-carnitine in carnitine-deficiency syndromes), but that does not extrapolate to a combined lipotropic-injection effect. There are no controlled trials of the fixed LIPO-C + B12 combination as a formulation. The recurring caution across both individual monographs applies doubly here: the marketed "metabolic support / energy" framing borrows B12's deficiency-correction evidence and LIPO-C's component biochemistry to imply a benefit in non-deficient users that the trial literature does not establish. LIPO-C is dispensed under 503A compounding authority, not FDA approval; B12's FDA approval covers deficiency, not the wellness-injection use.
Community protocol information.
In practice this is a clinic/compounding-pharmacy injection rather than a self-reconstituted research peptide: it is typically supplied pre-mixed and administered intramuscularly or subcutaneously on a set (often weekly) schedule defined by the compounder or clinic. Blend note: as a fixed mixture, the components cannot be titrated independently — one dose figure covers all of them — and there are no controlled pharmacokinetic or interaction data for this specific combination. A combination-specific wrinkle: because several LIPO-C base formulas already include B12, adding "Vitamin B12" can raise the cobalamin content without changing the label in any obvious way, so the compounder's actual formula (from the COA) should be checked before assuming how much B12 is present. Any dose figure should be treated as clinic/community practice, not a validated protocol, and read alongside the two individual monographs.
Stack combinations researchers commonly use.
This product is itself a stack — a multi-cofactor lipotropic blend plus a vitamin. In community and wellness-clinic practice it is most often discussed alongside GLP-1 receptor-agonist weight-management protocols (for example semaglutide or tirzepatide) and other "lipotropic" or B-complex injections. None of those extended combinations has controlled combination evidence; the rationale is additive cofactor/vitamin logic, and it remains preliminary at every level.
Storage and handling.
Store the solution refrigerated (2–8 °C) and protected from light: cobalamins are photodegradable (methylcobalamin notably more so than cyanocobalamin), and loss of the characteristic red colour indicates degradation. Beyond-use dating is assigned by the compounding pharmacy and varies by formula. As with any mixture, the preparation is only as stable as its least-stable component, so default to the most conservative storage window and beyond-use date among the ingredients.
Quality and COA considerations.
A meaningful COA for this product must do more than a single-compound COA: it should report identity and concentration for every component — each of the LIPO-C cofactors (methionine, choline, L-carnitine, the pantothenic-acid derivative) and the B12 — plus sterility, endotoxin, and a stability-grounded beyond-use date. Two component-specific checks matter here: disambiguate the B12 form (cyanocobalamin vs methylcobalamin; the canonical identity checks are the ~361 nm absorbance peak for cyanocobalamin and ~525 nm for methylcobalamin), and confirm whether B12 is already present in the LIPO-C base so it is not silently double-counted. Because compositions vary between compounders, a bare "LIPO-C + B12" label without a per-component breakdown is effectively unverified — treat the specific compounder and formulation as the identity.
Research-use note: This monograph is an educational summary of the composition, biochemistry, and community-reported practice for the LIPO-C + Vitamin B12 injection and its individual components. It is for laboratory and research use only. LIPO-C is a 503A compounding-pharmacy blend with no standardised formula and no Phase III support for its marketed body-composition indication; Vitamin B12 is FDA-approved for cobalamin deficiency but not for the "energy / metabolic support" use in non-deficient subjects implied by the product's marketing; there are no controlled trials of the fixed combination; blend dosing is more variable and less studied than single-compound dosing; and nothing here is medical advice or a usage recommendation.
Plum Labs Research — Order & leave a review to be entered for drawling for $300 store credit giveawayShop Now